Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma
Open Access
- 15 May 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (10) , 3472-3483
Abstract
Purpose: Histone deactylase inhibitors (HDACi) are a promising new class of anticancer therapeutics; however, little is known about HDACi activity in soft tissue sarcoma (STS), a heterogeneous cohort of mesenchymal origin malignancies. Consequently, we investigated the novel HDACi PCI-24781, alone/in combination with conventional chemotherapy, to determine its potential anti-STS–related effects and the underlying mechanisms involved.Keywords
This publication has 45 references indexed in Scilit:
- Combined Vascular Endothelial Growth Factor Receptor/Epidermal Growth Factor Receptor Blockade with Chemotherapy for Treatment of Local, Uterine, and Metastatic Soft Tissue SarcomaClinical Cancer Research, 2008
- Soft Tissue Sarcoma Cells Are Highly Sensitive to AKT Blockade: A Role for p53-Independent Up-regulation of GADD45αCancer Research, 2008
- HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombinationProceedings of the National Academy of Sciences, 2007
- Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitorProceedings of the National Academy of Sciences, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX fociMolecular Cancer Therapeutics, 2006
- CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivoMolecular Cancer Therapeutics, 2006
- Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approachesCancer Treatment Reviews, 2006
- CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTSAnnual Review of Pharmacology and Toxicology, 2005
- Direct repression of the Mcl-1 promoter by E2F1Oncogene, 2002